Abstract
The clinical and hormonal effects of spironolactone on the pituitary-testicular axis were evaluated in healthy, young men. One group of nine men took 100 mg daily for 4 weeks, none for 4 weeks, then 400 mg daily for 4 weeks. The dialyzable fraction of testosterone increased by 20% (P < 0.01) during both periods of spironolactone administration. The serum concentrations of FSH, LH, testosterone andestradiol, however, did not change during either period, nor did the FSH and LH responses to synthetic gonadotropin-releasing hormone. Another group of 9 men took 400 mg of spironolactone daily for up to 24 weeks. During this time6 developed gynecomastia and 2 noted a decrease in libido. Two men had decreases in sperm density and motility that were apparently drug-related, although the mean sperm density of all 9 men did not change significantly. No change occurred in the mean serum concentrations of FSH, LH, testosterone or estradiol. In vitro incubation of canrenone, the principal circulating metabolite of spir...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Clinical Endocrinology & Metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
